

Freeform Search

Database:	US Pre-Grant Publication Full-Text Database	
	US Patents Full-Text Database	
	US OCR Full-Text Database	
	EPO Abstracts Database	
	JPO Abstracts Database	
	Derwent World Patents Index	
	IBM Technical Disclosure Bulletins	
Term:	L18 NOT L16	
Display:	<input type="text" value="20"/>	Documents in Display Format: <input type="text" value="CIT"/>
		Starting with Number <input type="text" value="1"/>
Generate:	<input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image	

Search History

DATE: Friday, July 06, 2007
 [Purge Queries](#)
 [Printable Copy](#)
 [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L20	L18 NOT L16	22	L20
L19	L18 and @ad<20020620	13	L19
L18	L17 same ("propylene glycol" or "propane diol" or propanediol)	22	L18
L17	(muco\$8 near5 (polysaccharide or glycosaminoglycan or chondroitin or hyaluronic acid or dermatan or keratan or heparin or acemannan or "chondroitin sulfate" or "chondroitin sulphate" or "sodium hyaluronate" or hyaluronate)) same (nasal\$4 or mucos\$5)	2920	L17
L16	L15 and ("propylene glycol" or "propane diol" or propanediol)	12	L16
L15	L14 and @ad<20020620	30	L15
L14	L13 and (muco\$8 near5 (polysaccharide or glycosaminoglycan or chondroitin or hyaluronic acid or dermatan or keratan or heparin or acemannan or "chondroitin sulfate" or "chondroitin sulphate" or "sodium hyaluronate" or hyaluronate))	46	L14
L13	L12 same (nasal\$4 or mucos\$5)	964	L13
L12	(xylometazoline or naphazoline or fenoxazoline or oxymetazoline or tetrahydrozoline or tramazoline or phenylephrine or ephedrine or epinephrine)	19437	L12
	DB=PGPB,USPT; PLUR=YES; OP=OR		
L11	L10 and @ad<20020620	1	L11
L10	L9 and ("preservative-free" or (free near5 preservative))	8	L10

<u>L9</u>	L8 and ("propylene glycol" or "propane diol" or propanediol)	306	<u>L9</u>
<u>L8</u>	L7 and (chondroitin or hyaluronic acid or dermatan or keratan or heparin or acemannan or "chondroiten sulfate" or "chondroiten sulphate" or "sodium hyaluronate" or hyaluronate)	576	<u>L8</u>
<u>L7</u>	L6 and (xylometazoline or naphazoline or fenoxazoline or oxymetazoline or tetrahydrozoline or tramazoline or phenylephrine or ephedrine or epinephrine)	602	<u>L7</u>
<u>L6</u>	L5 and (nasal\$ or mucos\$4)	3916	<u>L6</u>
<u>L5</u>	(424/46 or 424/400 or 424/434 or 514/54 or 514/62 or 514/253.04 or 514/649 or 514/396 or 514/730).ccls.	12090	<u>L5</u>
<u>L4</u>	20050129622.pn.	1	<u>L4</u>
<u>L3</u>	(Urbano near Salvi) AND @pd>20061001	0	<u>L3</u>
<u>L2</u>	(Giovanna near Marzano) AND @pd>20061001	1	<u>L2</u>
<u>L1</u>	(Isabelle near Rault) AND @pd>20061001	1	<u>L1</u>

END OF SEARCH HISTORY



Day : Friday
Date: 7/6/2007
Time: 15:04:38

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

Rault

Isabelle

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Friday
Date: 7/6/2007
Time: 15:04:52

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Friday
Date: 7/6/2007
Time: 15:04:52

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

(FILE 'HOME' ENTERED AT 17:28:46 ON 06 JUL 2007)

FILE 'REGISTRY' ENTERED AT 17:28:52 ON 06 JUL 2007

 E "HYALURONIC ACID"/CN 25
L1 1 S E3
 E "CHONDROITIN SULFATE"/CN 25
L2 1 S E3

FILE 'CAPLUS, MEDLINE, USPATFULL, BIOSIS, EMBASE' ENTERED AT 17:31:18 ON
06 JUL 2007

L3 66699 S L1 OR L2
L4 127 S L3 (S) (NASAL? OR MUCOS?)
L5 0 S L4 (S) (VASOCONSTRIC? OR XYLOMETAZOLINE OR NAPHAZOLINE OR FE
L6 11 S L4 AND (VASOCONSTRIC? OR XYLOMETAZOLINE OR NAPHAZOLINE OR FE
L7 11 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)
L8 4 S L7 NOT PD>20020620
L9 4 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 17:39:24 ON 06 JUL 2007

=> d que L5

L1 1 SEA FILE=REGISTRY ABB=ON "HYALURONIC ACID"/CN
L2 1 SEA FILE=REGISTRY ABB=ON "CHONDROITIN SULFATE"/CN
L3 66699 SEA L1 OR L2
L4 127 SEA L3 (S) (NASAL? OR MUCOS?)
L5 0 SEA L4 (S) (VASOCONSTRIC? OR XYLOMETAZOLINE OR NAPHAZOLINE OR
 FENOXAZOLINE OR OXYMETAZOLINE OR TETRAHYDROZOLINE OR TRAMAZOLIN
 E OR PHENYLEPHRINE OR EPHEDRINE OR EPINEPHRINE)

=> d que L6

L1 1 SEA FILE=REGISTRY ABB=ON "HYALURONIC ACID"/CN
L2 1 SEA FILE=REGISTRY ABB=ON "CHONDROITIN SULFATE"/CN
L3 66699 SEA L1 OR L2
L4 127 SEA L3 (S) (NASAL? OR MUCOS?)
L6 11 SEA L4 AND (VASOCONSTRIC? OR XYLOMETAZOLINE OR NAPHAZOLINE OR
 FENOXAZOLINE OR OXYMETAZOLINE OR TETRAHYDROZOLINE OR TRAMAZOLIN
 E OR PHENYLEPHRINE OR EPHEDRINE OR EPINEPHRINE)

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 9007-28-7 REGISTRY
 CN Chondroitin, hydrogen sulfate (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Chondroitinsulfuric acids (8CI)
 OTHER NAMES:
 CN Chondroitin polysulfate
 CN Chondroitin sulfate
 CN Chondroitin sulphate
 CN Chondroitinsulfuric acid
 CN Chonsurid
 CN Cosamin DS
 CN Uracyst S 400
 DR 9046-20-2, 9062-29-7, 11120-14-2, 56480-79-6
 MF H2 O4 S . x Unspecified
 CI COM
 PCT Manual registration
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA,
 CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSChem, DDFU, DRUGU,
 EMBASE, IFICDB, IFIPAT, IFIUDb, IPA, MEDLINE, MRCK*, NAPRALERT, PHAR,
 PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 DT.CA CAplus document type: Conference; Dissertation; Journal; Patent; Report
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
 study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
 study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses)


 CM 1

 CRN 9007-27-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
 CMF H2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7026 REFERENCES IN FILE CA (1907 TO DATE)

499 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

7044 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 9004-61-9 REGISTRY
 CN Hyaluronic acid (CA INDEX NAME)
 OTHER NAMES:
 CN ACP
 CN ACP (polysaccharide)
 CN ACP gel
 CN Chlamyhyaluronic acid
 CN Cystitat
 CN Durolane
 CN FCH-SU
 CN Genzyme 9983
 CN HA 9
 CN Hy 20
 CN Hyal
 CN Hyalobarrier gel
 CN Hyalofill
 CN Hyaluronan
 CN Hyaluronsan HA-F
 CN Hylan G-F 20
 CN Hylartil
 CN Hyruan Plus
 CN Luronit
 CN Mucoitin
 CN Q 5AQ
 CN Restylane Perlane
 CN Sepracoat
 CN Sepragel Sinus
 CN Sofast
 CN Synvisc
 DR 165324-65-2, 9039-38-7, 37243-73-5, 29382-75-0
 MF Unspecified
 CI PMS, COM, MAN
 PCT Manual registration, Polyester, Polyester formed
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
 CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU,
 DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS,
 IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NAPRALERT, PATDPASPC,
 PHAR, PIRA, PROMT, PS, SCISEARCH, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent;
 Preprint; Report
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC
 (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);
 PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role
 in record)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
 study); BIOL (Biological study); MSC (Miscellaneous); PREP
 (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
 reagent); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
 study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC
 (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);
 PRP (Properties); RACT (Reactant or reagent); USES (Uses)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14766 REFERENCES IN FILE CA (1907 TO DATE)

1240 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

14829 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Cooling agents containing caffeine derivatives for pharmaceutical composition

AB The invention relates to a method for refrigerating a composition, especially mucosal

pharmaceutical composition, without causing unwanted sensory, e.g. unwanted odor and irritation, wherein the composition contains caffeine, theophylline, diprophylline, theobromine, proxyphylline, pentoxifylline, and/or related compound. An eye drop containing caffeine anhydride 3, tetrahydrozoline hydrochloride 0.5, neostigmine methylsulfate 0.05, pyridoxin hydrochloride 1, potassium aspartate 10, benzalchonium chloride 0.1, boric acid 5, NaOH q.s., and water q.s. to 1000 mL was formulated.

ACCESSION NUMBER: 2001:791880 CAPLUS

DOCUMENT NUMBER: 135:348877

TITLE: Cooling agents containing caffeine derivatives for pharmaceutical composition

INVENTOR(S): Matsushima, Hiroaki; Okumura, Shigetoshi; Morioka, Shigeo

PATENT ASSIGNEE(S): Rohto Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 2001302545	A	20011031	JP 2001-39116	20010215
PRIORITY APPLN. INFO.:			JP 2000-36557	A 20000215
OTHER SOURCE(S):	MARPAT 135:348877			

L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Method and agents for sensory improvement due to cooling agents

AB The invention relates to a method for improving sensory, e.g. irritation, due to cooling agent, e.g. menthol, camphor, and borneol, etc., used in a composition, especially a mucosal composition, wherein the method includes addition of

caffeine, theophylline, diprophylline, theobromine, proxyphylline, pentoxifylline, and/or related compound in the composition. An eye drop containing

caffeine anhydride 1, 1-menthol 0.02, NaCl 0.8, KCl 0.15, polysorbate 80, sodium dihydrogen phosphate 0.2, sodium chondroitin sulfate 0.1, borax 0.16, benzalkonium chloride 0.004 g, and water and pH adjusting agent q.s. to 100 mL was formulated.

ACCESSION NUMBER: 2001:788822 CAPLUS

DOCUMENT NUMBER: 135:348876

TITLE: Method and agents for sensory improvement due to cooling agents

INVENTOR(S): Matsushima, Hiroaki; Okumura, Shigetoshi

PATENT ASSIGNEE(S): Rohto Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 2001302518	A	20011031	JP 2001-39117	20010215
PRIORITY APPLN. INFO.:			JP 2000-36556	A 20000215
OTHER SOURCE(S):	MARPAT 135:348876			

L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Endoscopic mucosal excision using injection solutions containing biocompatible viscous polymeric substances

AB Endoscopic excision of mucosal lesions such as polyps and cancers are safely and reliably performed using gel-like injection solns. containing (a) mucopolysaccharides, preferably hyaluronic acid, its pharmaceutically-acceptable salts, its derivs., its analogs, and its complexes, or their parts as an essential ingredients and optionally (b) pharmaceutically acceptable pigments, e.g. indigo carmine and (c) hemostatic and vasoconstrictive agents, e.g. epinephrine. The solns. are injected into mucosal lesions to protrude the area to make operation easy. An aqueous solution of Na hyaluronate (0.5%) was submucosally injected into resected pig stomach. The mucosa steeply protruded within 30 s and the protrusion was retained after 10 min.

ACCESSION NUMBER: 2001:517637 CAPLUS

DOCUMENT NUMBER: 135:112046

TITLE: Endoscopic mucosal excision using injection solutions containing biocompatible viscous polymeric substances

INVENTOR(S): Yamamoto, Hironori

PATENT ASSIGNEE(S): Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2001192336	A	20010717	JP 2000-37240	20000111
PRIORITY APPLN. INFO.:			JP 2000-37240	20000111

L9 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of Biyantong nasal spray

AB The preparation of Biyantong nasal spray were studied. The Biyantong nasal spray was made of ciprofloxacin hydrochloride, sodium chloride, ephedrine hydrochloride, hyaluronic acid and Et p-hydroxybenzoate. The study included the preparation process, quality standard, stability test, irritability test and clin. application. This preparation had a rational composition, satisfactory stability, reliable effect, simple technol. requirement and no irritability. Biyantong spray could be produced by hospital pharmacy.

ACCESSION NUMBER: 2000:503943 CAPLUS

DOCUMENT NUMBER: 134:120808

TITLE: Preparation of Biyantong nasal spray

AUTHOR(S): Tang, Chao; Liu, Aiping; Li, Danping; Xiong, Dehua; Xu, Heqing; Chen, Dongfang; Wan, Jianyang

CORPORATE SOURCE: Hubei Country First People's Hospital of Xiantao, Xiantao, 433000, Peop. Rep. China

SOURCE: Zhongguo Yiyuan Yaoxue Zazhi (2000), 20(4), 221-222
CODEN: ZYYAEP; ISSN: 1001-5213

PUBLISHER: Zhongguo Yiyuan Yaoxue Zazhi Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

(FILE 'HOME' ENTERED AT 16:42:42 ON 06 JUL 2007)

FILE 'CAPLUS, MEDLINE, USPATFULL, EMBASE, BIOSIS' ENTERED AT 16:43:16 ON 06 JUL 2007

L1 273832 S (XYLOMETAZOLINE OR NAPHAZOLINE OR FENOXAZOLINE OR OXYMETAZOLI
L2 429360 S (CHONDROITIN OR HYALURONIC ACID OR DERMATAN OR KERATAN OR HEP
L3 5713 S L1 AND L2
L4 429360 S L2 (S) L2
L5 1811 S L3 AND (NASAL? OR MUCOS?)
L6 1811 S L3 (S) (NASAL? OR MUCOS?)
L7 870 S L5 AND ((PROPYLENE(W)GLYCOL) OR (PROPANE(2A)DIOL) OR PROPANE
L8 870 S L6 (S) ((PROPYLENE(W)GLYCOL) OR (PROPANE(2A)DIOL) OR PROPANE
L9 16 S L7 AND ((DEVOID OR FREE OR NO OR NONE) (5A) (PRESERVATIVE OR
L10 16 S L8 (S) ((DEVOID OR FREE OR NO OR NONE) (5A) (PRESERVATIVE OR
L11 16 DUPLICATE REMOVE L10 (0 DUPLICATES REMOVED)
L12 16 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)
L13 0 S L11 NOT PD>20020620
L14 0 S L10 NOT PD>20020620
L15 2 S L10 NOT PD>20030618
L16 2 S L11 NOT PD>20030618

=> d que L1

L1 273832 SEA (XYLOMETAZOLINE OR NAPHAZOLINE OR FENOXAZOLINE OR OXYMETAZO
LINE OR TETRAHYDROZOLINE OR TRAMAZOLINE OR PHENYLEPHRINE OR
EPHEDRINE OR EPINEPHRINE)

=> d que L2

L2 429360 SEA (CHONDROITIN OR HYALURONIC ACID OR DERMATAN OR KERATAN OR
HEPARIN OR ACEMANNAN OR (CHONDROITEN(W) SULFATE) OR (CHONDROITE
N(W) SULPHATE) OR (SODIUM(W) HYALURONATE) OR HYALURONATE OR
GLYCOSAMINOGLYCAN)

=> d que L7

L1 273832 SEA (XYLOMETAZOLINE OR NAPHAZOLINE OR FENOXAZOLINE OR OXYMETAZO
LINE OR TETRAHYDROZOLINE OR TRAMAZOLINE OR PHENYLEPHRINE OR
EPHEDRINE OR EPINEPHRINE)
L2 429360 SEA (CHONDROITIN OR HYALURONIC ACID OR DERMATAN OR KERATAN OR
HEPARIN OR ACEMANNAN OR (CHONDROITEN(W) SULFATE) OR (CHONDROITE
N(W) SULPHATE) OR (SODIUM(W) HYALURONATE) OR HYALURONATE OR
GLYCOSAMINOGLYCAN)
L3 5713 SEA L1 AND L2
L5 1811 SEA L3 AND (NASAL? OR MUCOS?)
L7 870 SEA L5 AND ((PROPYLENE(W) GLYCOL) OR (PROPANE(2A) DIOL) OR
PROPANEDIOL)

=> d que L8

L1 273832 SEA (XYLOMETAZOLINE OR NAPHAZOLINE OR FENOXAZOLINE OR OXYMETAZO
LINE OR TETRAHYDROZOLINE OR TRAMAZOLINE OR PHENYLEPHRINE OR
EPHEDRINE OR EPINEPHRINE)
L2 429360 SEA (CHONDROITIN OR HYALURONIC ACID OR DERMATAN OR KERATAN OR
HEPARIN OR ACEMANNAN OR (CHONDROITEN(W) SULFATE) OR (CHONDROITE
N(W) SULPHATE) OR (SODIUM(W) HYALURONATE) OR HYALURONATE OR
GLYCOSAMINOGLYCAN)
L3 5713 SEA L1 AND L2
L6 1811 SEA L3 (S) (NASAL? OR MUCOS?)
L8 870 SEA L6 (S) ((PROPYLENE(W) GLYCOL) OR (PROPANE(2A) DIOL) OR
PROPANEDIOL)

=> d que L9

L1 273832 SEA (XYLOMETAZOLINE OR NAPHAZOLINE OR FENOXAZOLINE OR OXYMETAZO
LINE OR TETRAHYDROZOLINE OR TRAMAZOLINE OR PHENYLEPHRINE OR
EPHEDRINE OR EPINEPHRINE)

L2 429360 SEA (CHONDROITIN OR HYALURONIC ACID OR DERMATAN OR KERATAN OR
HEPARIN OR ACEMANNAN OR (CHONDROITEN(W) SULFATE) OR (CHONDROITE
N(W) SULPHATE) OR (SODIUM(W) HYALURONATE) OR HYALURONATE OR
GLYCOSAMINOGLYCAN)

L3 5713 SEA L1 AND L2

L5 1811 SEA L3 AND (NASAL? OR MUCOS?)

L7 870 SEA L5 AND ((PROPYLENE(W) GLYCOL) OR (PROPANE(2A) DIOL) OR
PROPANEDIOL)

L9 16 SEA L7 AND ((DEVOID OR FREE OR NO OR NONE) (5A) (PRESERVATIVE
OR ANTIMICROBIAL OR (ANTI(2A) MICROBIAL) OR ANTIFUNGAL OR
ANTIBACTERIAL OR (BENZALKONIUM(W) CHLORIDE)))

=> d que L10

L1 273832 SEA (XYLOMETAZOLINE OR NAPHAZOLINE OR FENOXAZOLINE OR OXYMETAZO
LINE OR TETRAHYDROZOLINE OR TRAMAZOLINE OR PHENYLEPHRINE OR
EPHEDRINE OR EPINEPHRINE)

L2 429360 SEA (CHONDROITIN OR HYALURONIC ACID OR DERMATAN OR KERATAN OR
HEPARIN OR ACEMANNAN OR (CHONDROITEN(W) SULFATE) OR (CHONDROITE
N(W) SULPHATE) OR (SODIUM(W) HYALURONATE) OR HYALURONATE OR
GLYCOSAMINOGLYCAN)

L3 5713 SEA L1 AND L2

L6 1811 SEA L3 (S) (NASAL? OR MUCOS?)

L8 870 SEA L6 (S) ((PROPYLENE(W) GLYCOL) OR (PROPANE(2A) DIOL) OR
PROPANEDIOL)

L10 16 SEA L8 (S) ((DEVOID OR FREE OR NO OR NONE) (5A) (PRESERVATIVE
OR ANTIMICROBIAL OR (ANTI(2A) MICROBIAL) OR ANTIFUNGAL OR
ANTIBACTERIAL OR (BENZALKONIUM(W) CHLORIDE)))

L15 ANSWER 1 OF 2 USPATFULL on STN

TI Liquid formulations for the prevention and treatment of mucosal diseases and disorders

AB Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes, especially mucositis.

ACCESSION NUMBER: 2003:86878 USPATFULL

TITLE: Liquid formulations for the prevention and treatment of mucosal diseases and disorders

INVENTOR(S): Jacob, Jeremy E., Lewisville, TX, UNITED STATES
Nowotnik, David P., Colleyville, TX, UNITED STATES
Baud, Christiane M., Dallas, TX, UNITED STATES

PATENT ASSIGNEE(S): ACCESS PHARMACEUTICALS, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060486	A1	20030327
APPLICATION INFO.:	US 2002-219634	A1	20020815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-77459, filed on 15 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-269049P	20010215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Daniel S. Hodgins, JACKSON WALKER, LLP, Suite 2100, 112 E. Pecan, San Antonio, TX, 78205	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1043	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 2 OF 2 USPATFULL on STN

TI Method for identifying a compound to be tested for an ability to reduce immune rejection by determining Stat4 and Stat6 proteins

AB The present invention relates to methods for identifying compounds that can reduce immune rejection, for example, transplant- or autoimmune disorder-related immune rejection. The present invention is based, in part, on the discovery, demonstrated herein, that immune rejection can be monitored by determining the amount of particular members of the Jak/Stat signal transduction pathway present within an affected tissue. The present invention is further based, in part, on the discovery, demonstrated herein, that immune rejection can be reduced and tolerance can be induced by modulating the amount of these particular members of the Jak/Stat signal transduction pathway present, expressed or active within an affected tissue. In particular, the results demonstrate that immune rejection can be monitored by determining the amount of mRNA or protein of Stat1, Stat3, Stat4, Stat6, SOCS1, or SOCS3 present, e.g., in an affected tissue.

ACCESSION NUMBER: 2003:74268 USPATFULL

TITLE: Method for identifying a compound to be tested for an ability to reduce immune rejection by determining Stat4 and Stat6 proteins

INVENTOR(S): Hancock, Wayne William, Medfield, MA, United States
Ozkaynak, Engin, Milford, MA, United States

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6534277	B1	20030318

APPLICATION INFO.: US 2001-972800 20011005 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-549654, filed on 14
Apr 2000, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kemmerer, Elizabeth
ASSISTANT EXAMINER: Li, Ruixiang
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 69 Drawing Figure(s); 64 Drawing Page(s)
LINE COUNT: 7647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.